Cholestyramine is a bile acid sequestrant administered to aid management of lipid levels. Binding to bile salts reduces enterohepatic circulation, necessitating cholesterol conversion for continued bile acid synthesis.
Targeting the enterohepatic circulation, this anion-exchange resin belongs to a class that binds bile acids and helps reduce their reabsorption. The active compound is found in formulations such as Questran, where it serves as the therapeutic driver. By anchoring bile acids within the intestinal lumen, it indirectly influences cholesterol metabolism. Patients often encounter this ingredient when managing conditions linked to excess bile acids.
Formulated as tablets and powders, the resin appears in products such as Questran, offering both generic and branded options across Singapore’s pharmacy landscape. Local regulations require clear labeling of strength and excipients, allowing healthcare professionals to match the appropriate form to a patient’s needs. Tablet versions typically contain 4 g of the active resin per dose, while powder packets provide flexible mixing with water or food. Availability spans hospital dispensaries and community outlets.
Alleviating itching associated with cholestatic liver disease, the compound also supports modest cholesterol lowering in individuals with elevated lipid levels. It assists in controlling certain types of diarrhea where bile-acid malabsorption contributes to loose stools. Adult patients with primary biliary cholangitis and children with familial hypercholesterolemia may be prescribed products containing this resin. The therapeutic intent centers on managing symptoms rather than providing a cure.
Binding bile acids in the gut, the resin prevents their reabsorption, prompting the liver to draw on circulating cholesterol to synthesize new bile acids. This cycle modestly lowers blood cholesterol levels over time. Additionally, by removing bile acids that can irritate nerve endings, the resin reduces itching sensations linked to liver dysfunction. The action remains confined to the gastrointestinal tract, minimizing systemic exposure.
Mild gastrointestinal changes such as flatulence, constipation, or a feeling of fullness may occur shortly after starting therapy.
Severe abdominal pain, persistent vomiting, or signs of bowel obstruction signal a rare but urgent concern that requires immediate medical attention.
Pregnant individuals, nursing parents, and patients with known hypersensitivity to the resin should avoid use due to potential adverse effects.
Concurrent use of certain medications, especially those that rely on bile-acid-dependent absorption, may alter efficacy; patients should refer to the specific medication’s insert for an exact interaction list.
Storing the tablets in a cool, dry place helps maintain stability throughout the treatment course. Typical regimens last from several weeks for acute symptom relief to months for chronic lipid management, depending on the product. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This article provides an educational overview of the resin found in Questran and does not constitute medical advice. Individual medicines differ in strength, formulation, and instructions, which may affect outcomes. The publisher disclaims liability for any clinical application of this information. Patients should consult the specific medication labeling and a licensed healthcare professional for personalized guidance.
